EPILEPSY IN WOMEN: THE BIOLOGICAL BASIS FOR THE FEMALE EXPERIENCE

Supplement 2 to Volume 71, February 2004

SUPPLEMENT EDITORS:

Nancy Foldvary-Schaefer, DO The Cleveland Clinic Martha J. Morrell, MD Columbia University and The Neurological Institute

This supplement is based on the proceedings from an expert roundtable, titled "Epilepsy in Women: The Biological Basis for the Female Experience," held February 28, 2003, in New York, N.Y.

CONTENTS AND FACULTY

Introduction	S2
NANCY FOLDVARY-SCHAEFER, DO, AND MARTHA J. MORF	ell, MD
Cellular and molecular effects of steroid hormones on CNS excitability	S4
SHERYL S. SMITH, PHD, AND CATHERINE S. WOOLLEY	, PhD
Hormones and seizures Nancy Foldvary-Schaefer, DO; Cynthia Harden Andrew Herzog, MD; and Tommaso Falcone, M	, ,
Reproductive disturbances in patients with epilepsy Martha J. Morrell, MD, and Georgia D. Montou	S19
Risks and management of pregnancy in women with epilepsy	\$25
Mark S. Yerby, MD, MPH; Peter Kaplan, MB; and Teresa Tran, MD	

Neurodevelopmental outcomes of children born to mothers with epilepsy Kimford J. Meador, MD, and Mary L. Zupanc, ME	S38
Bone disease associated with antiepileptic drugs Alison M. Pack, MD; Barry Gidal, PharmD; and Blanca Vazquez, MD	S42
Recommendations for the care of women with epilepsy Patricia E. Penovich, MD; Karen E. Eck, MS, FNP and Vasiliki V. Economou, MD	S49

This supplement has been made possible through an educational grant from GlaxoSmithKline.

Topics and editors for supplements to the *Cleveland Clinic Journal of Medicine* are determined by the *Journal's* editor-in-chief and staff. Supplement editors are chosen for their expertise in the topics discussed and are responsible for the scientific quality of supplements, including the review process. The *Journal* ensures that supplement editors and authors fully disclose any relationships with industry, including the supplement underwriter. For full guidelines on grant-supported supplements to the *Journal*, go to www.ccjm.org/pdffiles/guidelines.pdf.

Copyright© 2004 The Cleveland Clinic Foundation.

The statements and opinions expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of The Cleveland Clinic Foundation, its Board of Trustees, the American Epilepsy Society, or GlaxoSmithKline.

The Cleveland Clinic Journal of Medicine (ISSN 0891-1150) is published 12 times yearly by The Cleveland Clinic Foundation.

Subscription rates: U.S. and possessions: personal \$98; institutional \$124; single copy/back issue \$16. Foreign: \$124; single copy/back issue \$16. Institutional (multiple-reader rate) applies to libraries, schools, hospitals, and federal, commercial, and private institutions and organizations. Individual subscriptions must be in the names of, billed to, and paid by individuals.

Postmaster address changes: Cleveland Clinic Journal of Medicine, NA32, 9500 Euclid Avenue, Cleveland, OH 44195. Subscription orders, editorial, reprint, and production offices (same address): (216) 444-2661 (phone); (216) 444-9385 (fax); ccjm@ccf.org (e-mail); www.ccjm.org (Web).

Printed in USA

AMP

FEBRUARY 2004 S1

CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 71 • SUPPLEMENT 2

Downloaded from www.ccjm.org on May 3, 2025. For personal use only. All other uses require permission.